A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Amlodipine and Olmesartran Medoxomil

First FDA approval2017-07-18
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.240/unit
8 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.294
Across all dosage forms in distribution.
Highest NADAC
$0.353
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema5 entries indexed · 4 visible
What is Amlodipine and Olmesartran Medoxomil used for?

Amlodipine and Olmesartran Medoxomil is a this drug class medication tracked in Medicare Part D.

Is there a generic for Amlodipine and Olmesartran Medoxomil?

No. Amlodipine and Olmesartran Medoxomil is brand-only with no generic equivalents currently in market.

How much does my plan pay for Amlodipine and Olmesartran Medoxomil?

Across 329 Part D plans, Amlodipine and Olmesartran Medoxomil averages $0.294/unit (NADAC). Lowest available: $0.240/unit. Highest in distribution: $0.353/unit.

Is Amlodipine and Olmesartran Medoxomil on the FDA shortage list?

No. Amlodipine and Olmesartran Medoxomil is not currently on the FDA Drug Shortage Database.

1 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (8 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.